Literature DB >> 1855275

Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides.

P M Terheggen1, B G Floot, E L Lempers, O van Tellingen, A C Begg, L den Engelse.   

Abstract

Cytotoxic effects of cis-diamminedichloroplatinum-(II) (cis-DDP) are thought to be mediated by binding to DNA. Studies on binding of cis-DDP to cellular DNA rely heavily on the availability of specific antibodies. We therefore raised and characterized four rabbit antisera: one against cis-DDP-modified DNA (antiserum NKI-A59) and three others against the cis-DDP-modified (di)nucleotides cis-Pt(NH3)2d(pApG) (NKI-A68), cis-Pt(NH3)2d(GMP)2 (NKI-A10), and Pt(NH3)3dGMP (NKI-A39). Reactivities to platinum compounds were determined in an enzyme-linked immunosorbent assay (ELISA) and in a quantitative immunocytochemical assay. In the ELISA, NKI-A59 showed a high affinity for DNA heavily substituted with either cis-DDP or CBDCA [cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)]; amounts of platinum per well giving 50% inhibition (IA50) were as low as 15 and 76 fmol, respectively. NKI-A59 also showed affinity to cis-DDP-modified poly[d(G-C)].poly[d(G-C)], poly(dC), and poly(dG). No affinity was found for trans-DDP [trans-diamminedichloro-platinum(II)]-modified DNA, enzymatically digested cis-DDP-DNA, or cis-DDP-DNA, or cis-DDP-modified poly(dA).poly(dT), oligo(dA)15.oligo(dT)15, oligo(dG)21, oligo(dG)42, or oligo(dAAAG)10. The efficiency of binding to cis-DDP-DNA decreased with decreasing DNA modification levels. Although other cis-DDP-DNA- and cis-DDP-(di)nucleotide-specific antisera have been identified, NKI-A59 is the first antiserum described that is suitable for the in situ detection of cis-DDP-DNA adducts at clinically relevant platinum levels. Adduct-specific immunostaining signals in cultured RIF-1 cells or rat liver paralleled platinum-DNA binding as measured by atomic absorption spectroscopy. The antisera NKI-A68, NKI-A10, and NKI-A39 showed high affinity for their corresponding haptens and varying affinity for non-hapten cis-DDP-DNA adducts. Their affinity for digested cis-DDP-modified DNA was up to 30 times that for intact cis-DDP-DNA. Neither NKI-A68 nor NKI-A10 resulted in specific immunocytochemical staining of cis-DDP-DNA adducts. We conclude that NKI-A68, NKI-A10, and NKI-A39 are suitable for platinum-DNA adduct analysis of digested DNA in ELISA and that NKI-A59 is suitable for platinum-DNA adduct detection at the single-cell level using immunocytochemical methods.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1855275     DOI: 10.1007/bf00685507

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  29 in total

1.  Monoclonal antibodies to DNA modified with cis- or trans-diamminedichloroplatinum(II).

Authors:  W I Sundquist; S J Lippard; B D Stollar
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

2.  Immunological detection of DNA damage caused by melphalan using monoclonal antibodies.

Authors:  M J Tilby; J M Styles; C J Dean
Journal:  Cancer Res       Date:  1987-03-15       Impact factor: 12.701

3.  Immunocytochemical study of the action of cis-dichlorodiamino platinum on the human metaphase chromosome.

Authors:  J Morin-Faure; M Marcollet
Journal:  Eur J Cell Biol       Date:  1983-05       Impact factor: 4.492

Review 4.  Fundamental studies with cisplatin.

Authors:  B Rosenberg
Journal:  Cancer       Date:  1985-05-15       Impact factor: 6.860

Review 5.  Covalent modification of DNA by antineoplastic agents.

Authors:  K Hemminki; D B Ludlum
Journal:  J Natl Cancer Inst       Date:  1984-11       Impact factor: 13.506

6.  Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.

Authors:  E Reed; R F Ozols; R Tarone; S H Yuspa; M C Poirier
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

7.  Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in rodent tissue sections.

Authors:  P M Terheggen; B G Floot; E Scherer; A C Begg; A M Fichtinger-Schepman; L den Engelse
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

8.  Influence of the degree of DNA modification on the immunochemical determination of cisplatin-DNA adduct levels.

Authors:  A M Fichtinger-Schepman; R A Baan; F Berends
Journal:  Carcinogenesis       Date:  1989-12       Impact factor: 4.944

9.  cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II).

Authors:  A M Fichtinger-Schepman; A T van Oosterom; P H Lohman; F Berends
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

10.  Polyclonal antibodies to quantitate cis-diamminedichloroplatinum(II)--DNA adducts in cancer patients and animal models.

Authors:  M C Poirier; E Reed; L A Zwelling; R F Ozols; C L Litterst; S H Yuspa
Journal:  Environ Health Perspect       Date:  1985-10       Impact factor: 9.031

View more
  8 in total

1.  Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells.

Authors:  R C Rietbroek; P J van de Vaart; J Haveman; F A Blommaert; A Geerdink; P J Bakker; C H Veenhof
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Detection of platinum-DNA adducts by 32P-postlabelling.

Authors:  F A Blommaert; C P Saris
Journal:  Nucleic Acids Res       Date:  1995-04-25       Impact factor: 16.971

3.  Development of an ultraperformance liquid chromatography/mass spectrometry method to quantify cisplatin 1,2 intrastrand guanine-guanine adducts.

Authors:  Irene M Baskerville-Abraham; Gunnar Boysen; J Mitchell Troutman; Esra Mutlu; Leonard Collins; Kathryn E Dekrafft; Wenbin Lin; Candice King; Stephen G Chaney; James A Swenberg
Journal:  Chem Res Toxicol       Date:  2009-05       Impact factor: 3.739

Review 4.  Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.

Authors:  George D Cimino; Chong-xian Pan; Paul T Henderson
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

5.  Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei.

Authors:  Bernd Liedert; Dick Pluim; Jan Schellens; Jürgen Thomale
Journal:  Nucleic Acids Res       Date:  2006-03-29       Impact factor: 16.971

6.  Immunocytochemical analysis of cisplatin-induced platinum-DNA adducts with double-fluorescence video microscopy.

Authors:  C Meijer; E G de Vries; W A Dam; M H Wilkinson; H Hollema; H J Hoekstra; N H Mulder
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Immunodetection of human topoisomerase I-DNA covalent complexes.

Authors:  Anand G Patel; Karen S Flatten; Kevin L Peterson; Thomas G Beito; Paula A Schneider; Angela L Perkins; Daniel A Harki; Scott H Kaufmann
Journal:  Nucleic Acids Res       Date:  2016-02-24       Impact factor: 16.971

8.  Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin.

Authors:  G Los; M J van Vugt; H M Pinedo
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.